Elite in Achondroplasia

Melita D. Irving

Ludwig Cancer Research Lausanne Branch, 
Lausanne, VD, CH 
Elite in Achondroplasia
Ludwig Cancer Research Lausanne Branch, 
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Melita Irving practices in Lausanne, Switzerland. Ms. Irving is rated as an Elite expert by MediFind in the treatment of Achondroplasia. Her top areas of expertise are Achondroplasia, Acanthosis Nigricans, Chondrodystrophy, X-Linked Spondyloepiphyseal Dysplasia Tarda, and Kidney Transplant.

Her clinical research consists of co-authoring 157 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 36 articles and participated in 2 clinical trials in the study of Achondroplasia.

Gender
Female

Locations

Ludwig Cancer Research Lausanne Branch, Lausanne, VD, Switzerland
Other Locations
Lausanne Branch, Lausanne, VD, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
Enrollment Status: Terminated
Publish Date: August 01, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
Enrollment Status: Completed
Publish Date: April 13, 2021
View 2 Less Clinical Trials

157 Total Publications

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.
Journal: Science advances
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Irving's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 16 Advanced Conditions
View All 51 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile